홈 > 시장보고서 > 의약품

시장보고서

상품코드

1841959

다낭성난소증후군용 보충제 시장 규모, 점유율, 동향 분석 보고서 : 성분별, 제형별, 적응증별, 판매 채널별, 지역별, 부문별 예측(2025-2033년)

Polycystic Ovary Syndrome Supplements Market Size, Share & Trends Analysis Report By Ingredient, By Dosage Form, By Indication, By Sales Channel, By Region, And Segment Forecasts, 2025 - 2033

발행일: 2025년 09월 | 리서치사:

Grand View Research | 페이지 정보: 영문 100 Pages | 배송안내 : 2-10일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

다낭성난소증후군용 보충제 시장 요약

전 세계 다낭성난소증후군용 보충제 시장 규모는 2024년에 12억 달러로 평가되며 2033년에는 38억 달러에 달할 것으로 예상되며, 2025년부터 2033년까지 14.29%의 CAGR로 성장할 것으로 예상됩니다.

이 산업은 전 세계적으로 다낭성난소증후군(PCOS)의 유병률 증가와 장기적인 건강 영향에 대한 인식이 높아짐에 따라 성장세를 보이고 있습니다.

PCOS는 가임기 여성에게 영향을 미치지만, 진단 능력의 향상과 교육 캠페인으로 더 많은 여성들이 조기에 진단을 받고 있습니다. 이러한 환자층의 확대는 자연적으로 증상을 관리하는 데 도움이 되는 솔루션에 대한 수요를 촉진하여 보충제 제조업체의 강력한 성장 기반을 조성하고 있습니다.

부문 대시보드
세계의 다낭성난소증후군용 보충제 시장 : 성분별 변동 분석
세계의 다낭성난소증후군용 보충제 시장 : 시장 규모 예측과 동향 분석, 성분별(2021-2033년)
미오이노시톨 기반 보충제
미량영양소, 오메가 3
허브 보충제
기타

제5장 다낭성난소증후군용 보충제 시장 : 제형별 추정·동향 분석

부문 대시보드
세계의 다낭성난소증후군용 보충제 시장 : 제형별 변동 분석
세계의 다낭성난소증후군용 보충제 시장 : 시장 규모 예측과 동향 분석, 제형별(2021-2033년)
캡슐, 정제
분말
구미
액체

제6장 다낭성난소증후군용 보충제 시장 : 적응증별 추정·동향 분석

부문 대시보드
세계의 다낭성난소증후군용 보충제 시장 : 적응증별 변동 분석
세계의 다낭성난소증후군용 보충제 시장 : 시장 규모 예측과 동향 분석, 적응증별(2021-2033년)
생리 주기 서포트
호르몬 조절
생식 능력 개선
여드름·피부 건강
기타

제7장 다낭성난소증후군용 보충제 시장 : 판매 채널별 추정·동향 분석

부문 대시보드
세계의 다낭성난소증후군용 보충제 시장 : 판매 채널별 변동 분석
세계의 다낭성난소증후군용 보충제 시장 : 시장 규모 예측과 동향 분석, 판매 채널별(2021-2033년)
하이퍼마켓과 슈퍼마켓
약국·드럭스토어
온라인 매장

제8장 다낭성난소증후군용 보충제 시장 : 지역별 추정·동향 분석

시장 점유율 : 지역별(2024년·2033년)
시장 대시보드 : 지역별
시장 규모 예측과 동향 분석(2021-2033년)
북미
- 미국
- 캐나다
- 멕시코
유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 노르웨이
- 스웨덴
- 덴마크
아시아태평양
- 일본
- 중국
- 인도
- 호주
- 한국
- 태국
라틴아메리카
- 브라질
- 아르헨티나
중동 및 아프리카
- 남아프리카공화국
- 사우디아라비아
- 아랍에미리트
- 쿠웨이트

제9장 경쟁 구도

기업/경쟁 분류
전략 매핑
기업 시장 상황 분석(2024년)
기업 개요/상장 기업
- Himalaya Wellness
- Theralogix
- Allara Health
- The S'moo Co.
- Fertility Family
- SOVA
- MyOva
- Black Girl Vitamins
- New Leaf Products
- Zazzee Naturals

KSM 25.11.05

Polycystic Ovary Syndrome Supplements Market Summary

The global polycystic ovary syndrome supplements market size was valued at USD 1.20 billion in 2024 and is projected to reach USD 3.80 billion by 2033, growing at a CAGR of 14.29% from 2025 to 2033. The industry is gaining momentum due to the rising prevalence of polycystic ovary syndrome (PCOS) worldwide and growing awareness of its long-term health implications.

PCOS affects women of reproductive age, and with improving diagnostic capabilities and education campaigns, more women are being diagnosed earlier. This expanding patient pool is fueling demand for solutions that can help manage symptoms naturally, creating a strong growth base for supplement manufacturers.

Global Polycystic Ovary Syndrome Supplements Market Report Segmentation

This report forecasts revenue growth at the global, regional and country levels and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global polycystic ovary syndrome (PCOS) supplements market report on the basis of ingredient, dosage form, indication, sales channel, and region.

Ingredient Outlook (Revenue, USD Million, 2021 - 2033)
Myo inositol-based supplements
Micronutrient & Omega-3
Herbal Supplements
Others
Dosage Form Outlook (Revenue, USD Million, 2021 - 2033)
Capsules & tablets
Powders
Gummies
Liquids
Indication Outlook (Revenue, USD Million, 2021 - 2033)
Menstrual Cycle Support
Hormonal Regulation
Fertility Improvement
Acne and Skin Health
Others
Sales Channel Outlook (Revenue, USD Million, 2021 - 2033)
Hypermarket & Supermarket
Pharmacy & Drug stores
Online Stores
Regional Outlook (Revenue, USD Million, 2021 - 2033)
North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- UK
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Thailand
Latin America
- Brazil
- Argentina
MEA
- South Africa
- Saudi Arabia
- UAE
- Kuwait

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
1.2. Market Definitions
- 1.2.1. Ingredient Segment
- 1.2.2. Dosage Form Segment
- 1.2.3. Indication Segment
- 1.2.4. Sales Channel Segment
1.3. Information Analysis
- 1.3.1. Market formulation & data visualization
1.4. Data Validation & Publishing
1.5. Information Procurement
- 1.5.1. Primary Research
1.6. Information or Data Analysis
1.7. Market Formulation & Validation
1.8. Market Model
1.9. Total Market: CAGR Calculation
1.10. Objectives
- 1.10.1. Objective 1
- 1.10.2. Objective 2

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Insights Landscape

Chapter 3. Polycystic Ovary Syndrome Supplements Market Variables, Trends & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook.
3.2. Market Dynamics
- 3.2.1. Market driver analysis
  - 3.2.1.1. Rising global prevalence of PCOS
  - 3.2.1.2. Expansion of E-Commerce and DTC supplement brands
- 3.2.2. Market restraint analysis
  - 3.2.2.1. Lack of stringent regulation
  - 3.2.2.2. Low awareness in emerging markets
3.3. Polycystic Ovary Syndrome Supplements Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
- 3.3.2. PESTEL Analysis

Chapter 4. Polycystic Ovary Syndrome Supplements Market: Ingredients Estimates & Trend Analysis

4.1. Segment Dashboard
4.2. Global Polycystic Ovary Syndrome Supplements Market Ingredients Movement Analysis
4.3. Global Polycystic Ovary Syndrome Supplements Market Size & Trend Analysis, by Ingredients, 2021 to 2033 (USD Million)
4.4. Myo-inositol-based Supplements
- 4.4.1. Myo-inositol-based supplements market estimates and forecasts 2021 to 2033 (USD Million)
4.5. Micronutrient & Omega-3
- 4.5.1. Micronutrient & omega-3 market estimates and forecasts 2021 to 2033 (USD Million)
4.6. Herbal Supplements
- 4.6.1. Herbal supplements market estimates and forecasts 2021 to 2033 (USD Million)
4.7. Others
- 4.7.1. Others market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Polycystic Ovary Syndrome Supplements Market: Dosage Form Estimates & Trend Analysis

5.1. Segment Dashboard
5.2. Global Polycystic Ovary Syndrome Supplements Market Dosage Form Movement Analysis
5.3. Global Polycystic Ovary Syndrome Supplements Market Size & Trend Analysis, by Dosage Form, 2021 to 2033 (USD Million)
5.4. Capsules & Tablets
- 5.4.1. Capsules & tablets market estimates and forecasts 2021 to 2033 (USD Million)
5.5. Powders
- 5.5.1. Powders market estimates and forecasts 2021 to 2033 (USD Million)
5.6. Gummies
- 5.6.1. Gummies market estimates and forecasts 2021 to 2033 (USD Million)
5.7. Liquids
- 5.7.1. Liquids market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Polycystic Ovary Syndrome Supplements Market: Indication Estimates & Trend Analysis

6.1. Segment Dashboard
6.2. Global Polycystic Ovary Syndrome Supplements Market Indication Movement Analysis
6.3. Global Polycystic Ovary Syndrome Supplements Market Size & Trend Analysis, by Indication, 2021 to 2033 (USD Million)
6.4. Menstrual Cycle Support
- 6.4.1. Menstrual cycle support market estimates and forecasts 2021 to 2033 (USD Million)
6.5. Hormonal Regulation
- 6.5.1. Hormonal regulation market estimates and forecasts 2021 to 2033 (USD Million)
6.6. Fertility Improvement
- 6.6.1. Fertility improvement market estimates and forecasts 2021 to 2033 (USD Million)
6.7. Acne and Skin Health
- 6.7.1. Acne and skin health market estimates and forecasts 2021 to 2033 (USD Million)
6.8. Others
- 6.8.1. Others market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Polycystic Ovary Syndrome Supplements Market: Sales Channel Estimates & Trend Analysis

7.1. Segment Dashboard
7.2. Global Polycystic Ovary Syndrome Supplements Market Sales Channel Movement Analysis
7.3. Global Polycystic Ovary Syndrome Supplements Market Size & Trend Analysis, by Sales Channel, 2021 to 2033 (USD Million)
7.4. Hypermarket & Supermarket
- 7.4.1. Hypermarket & supermarket market estimates and forecasts 2021 to 2033 (USD Million)
7.5. Pharmacy & Drug stores
- 7.5.1. Pharmacy & drug stores market estimates and forecasts 2021 to 2033 (USD Million)
7.6. Online Stores
- 7.6.1. Online stores market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Polycystic Ovary Syndrome Supplements Market: Regional Estimates & Trend Analysis

8.1. Regional Market Share Analysis, 2024 & 2033
8.2. Regional Market Dashboard
8.3. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
8.4. North America
- 8.4.1. U.S.
  - 8.4.1.1. Key country dynamics
  - 8.4.1.2. Competitive scenario
  - 8.4.1.3. Regulatory Framework
  - 8.4.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
- 8.4.2. Canada
  - 8.4.2.1. Key country dynamics
  - 8.4.2.2. Competitive scenario
  - 8.4.2.3. Regulatory Framework
  - 8.4.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
- 8.4.3. Mexico
  - 8.4.3.1. Key country dynamics
  - 8.4.3.2. Competitive scenario
  - 8.4.3.3. Regulatory Framework
  - 8.4.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
8.5. Europe
- 8.5.1. UK
  - 8.5.1.1. Key country dynamics
  - 8.5.1.2. Competitive scenario
  - 8.5.1.3. Regulatory Framework
  - 8.5.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
- 8.5.2. Germany
  - 8.5.2.1. Key country dynamics
  - 8.5.2.2. Competitive scenario
  - 8.5.2.3. Regulatory Framework
  - 8.5.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
- 8.5.3. France
  - 8.5.3.1. Key country dynamics
  - 8.5.3.2. Competitive scenario
  - 8.5.3.3. Regulatory Framework
  - 8.5.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
- 8.5.4. Italy
  - 8.5.4.1. Key country dynamics
  - 8.5.4.2. Competitive scenario
  - 8.5.4.3. Regulatory Framework
  - 8.5.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
- 8.5.5. Spain
  - 8.5.5.1. Key country dynamics
  - 8.5.5.2. Competitive scenario
  - 8.5.5.3. Regulatory Framework
  - 8.5.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
- 8.5.6. Norway
  - 8.5.6.1. Key country dynamics
  - 8.5.6.2. Competitive scenario
  - 8.5.6.3. Regulatory Framework
  - 8.5.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
- 8.5.7. Sweden
  - 8.5.7.1. Key country dynamics
  - 8.5.7.2. Competitive scenario
  - 8.5.7.3. Regulatory Framework
  - 8.5.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
- 8.5.8. Denmark
  - 8.5.8.1. Key country dynamics
  - 8.5.8.2. Competitive scenario
  - 8.5.8.3. Regulatory Framework
  - 8.5.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
8.6. Asia Pacific
- 8.6.1. Japan
  - 8.6.1.1. Key country dynamics
  - 8.6.1.2. Competitive scenario
  - 8.6.1.3. Regulatory Framework
  - 8.6.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
- 8.6.2. China
  - 8.6.2.1. Key country dynamics
  - 8.6.2.2. Competitive scenario
  - 8.6.2.3. Regulatory Framework
  - 8.6.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
- 8.6.3. India
  - 8.6.3.1. Key country dynamics
  - 8.6.3.2. Competitive scenario
  - 8.6.3.3. Regulatory Framework
  - 8.6.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
- 8.6.4. Australia
  - 8.6.4.1. Key country dynamics
  - 8.6.4.2. Competitive scenario
  - 8.6.4.3. Regulatory Framework
  - 8.6.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
- 8.6.5. South Korea
  - 8.6.5.1. Key country dynamics
  - 8.6.5.2. Competitive scenario
  - 8.6.5.3. Regulatory Framework
  - 8.6.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
- 8.6.6. Thailand
  - 8.6.6.1. Key country dynamics
  - 8.6.6.2. Competitive scenario
  - 8.6.6.3. Regulatory Framework
  - 8.6.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
8.7. Latin America
- 8.7.1. Brazil
  - 8.7.1.1. Key country dynamics
  - 8.7.1.2. Competitive scenario
  - 8.7.1.3. Regulatory Framework
  - 8.7.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
- 8.7.2. Argentina
  - 8.7.2.1. Key country dynamics
  - 8.7.2.2. Competitive scenario
  - 8.7.2.3. Regulatory Framework
  - 8.7.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
8.8. MEA
- 8.8.1. South Africa
  - 8.8.1.1. Key country dynamics
  - 8.8.1.2. Competitive scenario
  - 8.8.1.3. Regulatory Framework
  - 8.8.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
- 8.8.2. Saudi Arabia
  - 8.8.2.1. Key country dynamics
  - 8.8.2.2. Competitive scenario
  - 8.8.2.3. Regulatory Framework
  - 8.8.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
- 8.8.3. UAE
  - 8.8.3.1. Key country dynamics
  - 8.8.3.2. Competitive scenario
  - 8.8.3.3. Regulatory Framework
  - 8.8.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
- 8.8.4. Kuwait
  - 8.8.4.1. Key country dynamics
  - 8.8.4.2. Competitive scenario
  - 8.8.4.3. Regulatory Framework
  - 8.8.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 9. Competitive Landscape

9.1. Company/Competition Categorization
9.2. Strategy Mapping
9.3. Company Market Position Analysis, 2024
9.4. Company Profiles/Listing
- 9.4.1. Himalaya Wellness
  - 9.4.1.1. Company overview
  - 9.4.1.2. Financial performance
  - 9.4.1.3. Product/Service benchmarking
  - 9.4.1.4. Strategic initiatives
- 9.4.2. Theralogix
  - 9.4.2.1. Company overview
  - 9.4.2.2. Financial performance
  - 9.4.2.3. Product/Service benchmarking
  - 9.4.2.4. Strategic initiatives
- 9.4.3. Allara Health
  - 9.4.3.1. Company overview
  - 9.4.3.2. Financial performance
  - 9.4.3.3. Product/Service benchmarking
  - 9.4.3.4. Strategic initiatives
- 9.4.4. The S'moo Co.
  - 9.4.4.1. Company overview
  - 9.4.4.2. Financial performance
  - 9.4.4.3. Product/Service benchmarking
  - 9.4.4.4. Strategic initiatives
- 9.4.5. Fertility Family
  - 9.4.5.1. Company overview
  - 9.4.5.2. Financial performance
  - 9.4.5.3. Product/Service benchmarking
  - 9.4.5.4. Strategic initiatives
- 9.4.6. SOVA
  - 9.4.6.1. Company overview
  - 9.4.6.2. Financial performance
  - 9.4.6.3. Product/Service benchmarking
  - 9.4.6.4. Strategic initiatives
- 9.4.7. MyOva
  - 9.4.7.1. Company overview
  - 9.4.7.2. Financial performance
  - 9.4.7.3. Product/Service benchmarking
  - 9.4.7.4. Strategic initiatives
- 9.4.8. Black Girl Vitamins
  - 9.4.8.1. Company overview
  - 9.4.8.2. Financial performance
  - 9.4.8.3. Product/Service benchmarking
  - 9.4.8.4. Strategic initiatives
- 9.4.9. New Leaf Products
  - 9.4.9.1. Company overview
  - 9.4.9.2. Financial performance
  - 9.4.9.3. Product/Service benchmarking
  - 9.4.9.4. Strategic initiatives
- 9.4.10. Zazzee Naturals
  - 9.4.10.1. Company overview
  - 9.4.10.2. Financial performance
  - 9.4.10.3. Product/Service benchmarking
  - 9.4.10.4. Strategic initiatives

02-2025-2992
(주말 및 공휴일 제외)

라이선스 / 가격

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 5,950

￦ 8,704,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 6,950

￦ 10,167,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

US $ 8,950

￦ 13,093,000

※ 부가세 별도